Market Overview:
The global tumor marker testing market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of cancer, technological advancements in tumor marker testing, and rising demand for personalized medicine. Based on type, the global tumor marker testing market is segmented into biochemical markers, oncogenes, growth factors, hormones, colony stimulating factors (CSFs), lymphokines, immunohistochemical stains (IHCs), and others. Biochemical markers are further sub-segmented into enzymes and proteins. Oncogenes are classified as proto-oncogenes and oncoproteins. Growth factors include epidermal growth factor (EGF) and fibroblast growth factor (FGF). Hormones include estrogen receptor (ER) and progesterone receptor (PR). CSFs comprise granulocyte colony-stimulating factor (G-CSF), macrophage colony-stimulating factor MCSF ), erythropoietin EPO ), interleukin ILs ), tumour necrosis factor alpha TNFα )and others which includes vascular endothelial cell growthfactor VEGFA ). IHCs are further sub segmented into HER2/neu protein overexpression assay kit , Ki67 antigen expression assay kit , p53 protein expression assay kit .
Product Definition:
Tumor marker testing is a type of laboratory test that is used to help diagnose certain cancers. The most common tumor markers are proteins or chemicals that are released into the blood or urine by tumors.
Biochemical Markers:
Biochemical markers are substances that are produced in high quantities by cancer cells and can be used to detect the presence of cancer. Biochemical markers act as a biomarker when they get released into the bloodstream, urine or other body fluids due to cell damage or death and can identify tumors.
Oncogenes:
Oncogenes are genes that promote the development of cancer. There are many oncogenes but some of the most common ones include BRCA1 & 2, TP53, and HRAS. These genes act as “seed” or “building blocks” for developing a malignant tumor. The presence or absence of these genetic mutations can be detected by using mutation-specific molecular diagnostic tests (such as FISH).
Application Insights:
The other application segment includes research studies. Other applications of tumor markers include research studies in the field of cancer biology, which require blood samples for biomarker analysis. Tumor marker testing is used as a diagnostic tool in various clinical settings including hospitals, clinics and Ambulatory Care Centers (ACCs), commercial/private laboratories, and physician offices/group practices.
In 2017, the hospital setting dominated the market with a revenue-based share of over 60%. This is due to factors such as an increase in number of patients suffering from cancer across the globe coupled with rising awareness about early diagnosis resulting in improved treatment outcomes. In addition, increasing R&D investments by major players such as GSK and Pfizer are expected to drive growth over the forecast period.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, availability of advanced technologies and high adoption rate for novel diagnostic approaches. Moreover, increasing prevalence of cancer is also one of the major factors responsible for regional growth. For instance, as per statistics published by American Cancer Society in 2018, around 1,762 new cases were reported in U.S., which translates into a 13% increase compared to 2016 and this number is anticipated to go up due to higher levels of obesity and smoking prevalence rates among population [1]. Thus all these factors are expected favorably impact the market over next eight years as well.
Asia Pacific region is estimated to witness lucrative growth during the forecast period owing to rising disposable income coupled with growing awareness about early diagnosis amongst patients; thus resulting into increased demand for such services & products from this region [2].
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for tumor marker testing market. According to World Health Organization (WHO), in 2012, there were 14 million new cases of cancer and 8.2 million deaths from the disease worldwide. This number is expected to increase to 21 million new cases and 13 million deaths by 2030. Thus, rising prevalence of cancer is fueling demand for tumor marker testing products and services worldwide.
- Growing awareness about benefits of early diagnosis: There is growing awareness among people about benefits of early diagnosis through tumor marker testing products and services for various types of cancers such as breast, ovarian, prostate, colorectal etc., which is propelling demand for these products and services globally.
Scope Of The Report
Report Attributes
Report Details
Report Title
Tumor Marker Testing Market Research Report
By Type
Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines, Immunohistochemical Stains, Others
By Application
Hospitals, Commercial/Private Laboratories, Physician Offices/Group Practices, Cancer Clinics, Ambulatory Care Centers
By Companies
Abbott Diagnostics, Affymetrix, Agilent Technologies, Beckman Dickinson（BD）, BioCurex, BioModa, Clarient, Correlogic Systems, Epigenomics, Hologic, Roche Diagnostics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
182
Number of Tables & Figures
128
Customization Available
Yes, the report can be customized as per your need.
Global Tumor Marker Testing Market Report Segments:
The global Tumor Marker Testing market is segmented on the basis of:
Types
Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines, Immunohistochemical Stains, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Commercial/Private Laboratories, Physician Offices/Group Practices, Cancer Clinics, Ambulatory Care Centers
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott Diagnostics
- Affymetrix
- Agilent Technologies
- Beckman Dickinson（BD）
- BioCurex
- BioModa
- Clarient
- Correlogic Systems
- Epigenomics
- Hologic
- Roche Diagnostics
Highlights of The Tumor Marker Testing Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Biochemical Markers
- Oncogenes
- Growth Factors
- Hormones
- Colony Stimulating Factors
- Lymphokines
- Immunohistochemical Stains
- Others
- By Application:
- Hospitals
- Commercial/Private Laboratories
- Physician Offices/Group Practices
- Cancer Clinics
- Ambulatory Care Centers
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Tumor Marker Testing Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Tumor marker testing is a type of cancer screening that uses blood or urine samples to look for signs of cancer. Tumor markers are substances in the blood or urine that can be used to help diagnose cancer.
Some of the major players in the tumor marker testing market are Abbott Diagnostics, Affymetrix, Agilent Technologies, Beckman Dickinson¯Â¼Ë†BD¯Â¼â€°, BioCurex, BioModa, Clarient, Correlogic Systems, Epigenomics, Hologic, Roche Diagnostics.
The tumor marker testing market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Tumor Marker Testing Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Tumor Marker Testing Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Tumor Marker Testing Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Tumor Marker Testing Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Tumor Marker Testing Market Size & Forecast, 2018-2028
4.5.1 Tumor Marker Testing Market Size and Y-o-Y Growth
4.5.2 Tumor Marker Testing Market Absolute $ Opportunity
Chapter 5 Global Tumor Marker Testing Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Tumor Marker Testing Market Size Forecast by Type
5.2.1 Biochemical Markers
5.2.2 Oncogenes
5.2.3 Growth Factors
5.2.4 Hormones
5.2.5 Colony Stimulating Factors
5.2.6 Lymphokines
5.2.7 Immunohistochemical Stains
5.2.8 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Tumor Marker Testing Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Tumor Marker Testing Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Commercial/Private Laboratories
6.2.3 Physician Offices/Group Practices
6.2.4 Cancer Clinics
6.2.5 Ambulatory Care Centers
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Tumor Marker Testing Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Tumor Marker Testing Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Tumor Marker Testing Analysis and Forecast
9.1 Introduction
9.2 North America Tumor Marker Testing Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Tumor Marker Testing Market Size Forecast by Type
9.6.1 Biochemical Markers
9.6.2 Oncogenes
9.6.3 Growth Factors
9.6.4 Hormones
9.6.5 Colony Stimulating Factors
9.6.6 Lymphokines
9.6.7 Immunohistochemical Stains
9.6.8 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Tumor Marker Testing Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Commercial/Private Laboratories
9.10.3 Physician Offices/Group Practices
9.10.4 Cancer Clinics
9.10.5 Ambulatory Care Centers
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Tumor Marker Testing Analysis and Forecast
10.1 Introduction
10.2 Europe Tumor Marker Testing Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Tumor Marker Testing Market Size Forecast by Type
10.6.1 Biochemical Markers
10.6.2 Oncogenes
10.6.3 Growth Factors
10.6.4 Hormones
10.6.5 Colony Stimulating Factors
10.6.6 Lymphokines
10.6.7 Immunohistochemical Stains
10.6.8 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Tumor Marker Testing Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Commercial/Private Laboratories
10.10.3 Physician Offices/Group Practices
10.10.4 Cancer Clinics
10.10.5 Ambulatory Care Centers
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Tumor Marker Testing Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Tumor Marker Testing Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Tumor Marker Testing Market Size Forecast by Type
11.6.1 Biochemical Markers
11.6.2 Oncogenes
11.6.3 Growth Factors
11.6.4 Hormones
11.6.5 Colony Stimulating Factors
11.6.6 Lymphokines
11.6.7 Immunohistochemical Stains
11.6.8 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Tumor Marker Testing Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Commercial/Private Laboratories
11.10.3 Physician Offices/Group Practices
11.10.4 Cancer Clinics
11.10.5 Ambulatory Care Centers
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Tumor Marker Testing Analysis and Forecast
12.1 Introduction
12.2 Latin America Tumor Marker Testing Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Tumor Marker Testing Market Size Forecast by Type
12.6.1 Biochemical Markers
12.6.2 Oncogenes
12.6.3 Growth Factors
12.6.4 Hormones
12.6.5 Colony Stimulating Factors
12.6.6 Lymphokines
12.6.7 Immunohistochemical Stains
12.6.8 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Tumor Marker Testing Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Commercial/Private Laboratories
12.10.3 Physician Offices/Group Practices
12.10.4 Cancer Clinics
12.10.5 Ambulatory Care Centers
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Tumor Marker Testing Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Tumor Marker Testing Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Tumor Marker Testing Market Size Forecast by Type
13.6.1 Biochemical Markers
13.6.2 Oncogenes
13.6.3 Growth Factors
13.6.4 Hormones
13.6.5 Colony Stimulating Factors
13.6.6 Lymphokines
13.6.7 Immunohistochemical Stains
13.6.8 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Tumor Marker Testing Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Commercial/Private Laboratories
13.10.3 Physician Offices/Group Practices
13.10.4 Cancer Clinics
13.10.5 Ambulatory Care Centers
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Tumor Marker Testing Market: Competitive Dashboard
14.2 Global Tumor Marker Testing Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Abbott Diagnostics
14.3.2 Affymetrix
14.3.3 Agilent Technologies
14.3.4 Beckman Dickinson（BD）
14.3.5 BioCurex
14.3.6 BioModa
14.3.7 Clarient
14.3.8 Correlogic Systems
14.3.9 Epigenomics
14.3.10 Hologic
14.3.11 Roche Diagnostics
